Allman KD - Search Results

1

Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma.

Gupta R, Ornstein MC, Li H, Allman KD, Wood LS, Gilligan T, Garcia JA, Merveldt DV, Hammers HJ, Rini BI. Gupta R, et al. Among authors: allman kd. Clin Genitourin Cancer. 2020 Dec;18(6):429-435. doi: 10.1016/j.clgc.2019.11.012. Epub 2019 Dec 5. Clin Genitourin Cancer. 2020. PMID: 32800717

2

Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood L, Elson P, Allman K, Beach J, Martin A, Gilligan T, Garcia JA, Rini BI. Ornstein MC, et al. Clin Genitourin Cancer. 2017 Apr;15(2):e275-e280. doi: 10.1016/j.clgc.2016.08.014. Epub 2016 Aug 18. Clin Genitourin Cancer. 2017. PMID: 27625016

3

A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma.

Ornstein MC, Wood LS, Elson P, Allman KD, Beach J, Martin A, Zanick BR, Grivas P, Gilligan T, Garcia JA, Rini BI. Ornstein MC, et al. Among authors: allman kd. J Clin Oncol. 2017 Jun 1;35(16):1764-1769. doi: 10.1200/JCO.2016.71.1184. Epub 2017 Jan 23. J Clin Oncol. 2017. PMID: 28113029 Clinical Trial.

4

Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies.

Barata PC, Gopalakrishnan D, Koshkin VS, Mendiratta P, Karafa M, Allman K, Martin A, Beach J, Profusek P, Tyler A, Wood L, Ornstein M, Gilligan T, Rini BI, Garcia JA, Grivas P. Barata PC, et al. Target Oncol. 2018 Jun;13(3):353-361. doi: 10.1007/s11523-018-0561-6. Target Oncol. 2018. PMID: 29623487

5

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.

Barata PC, De Liano AG, Mendiratta P, Crolley V, Szabados B, Morrison L, Wood L, Allman K, Tyler A, Martin A, Gilligan T, Grivas P, Ornstein M, Garcia JA, Powles T, Rini BI. Barata PC, et al. Br J Cancer. 2018 Jul;119(2):160-163. doi: 10.1038/s41416-018-0104-z. Epub 2018 May 24. Br J Cancer. 2018. PMID: 29795307 Free PMC article.

6

The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.

Chen YW, Ornstein MC, Wood LS, Allman KD, Martin A, Beach J, Gilligan T, Garcia JA, Rini BI. Chen YW, et al. Among authors: allman kd. Urol Oncol. 2018 Oct;36(10):470.e19-470.e29. doi: 10.1016/j.urolonc.2018.06.013. Epub 2018 Aug 18. Urol Oncol. 2018. PMID: 30131292

7

Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.

Zahoor H, Barata PC, Jia X, Martin A, Allman KD, Wood LS, Gilligan TD, Grivas P, Ornstein MC, Garcia JA, Rini BI. Zahoor H, et al. Among authors: allman kd. J Immunother Cancer. 2018 Oct 17;6(1):107. doi: 10.1186/s40425-018-0425-8. J Immunother Cancer. 2018. PMID: 30333065 Free PMC article.

8

Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.

Ornstein MC, Calabrese C, Wood LS, Kirchner E, Profusek P, Allman KD, Martin A, Kontzias A, Grivas P, Garcia JA, Calabrese LH, Rini BI. Ornstein MC, et al. Among authors: allman kd. Clin Genitourin Cancer. 2019 Jun;17(3):177-182. doi: 10.1016/j.clgc.2019.01.021. Epub 2019 Feb 7. Clin Genitourin Cancer. 2019. PMID: 30824360

9

A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy.

Ornstein MC, Wood LS, Hobbs BP, Allman KD, Martin A, Bevan M, Gilligan TD, Garcia JA, Rini BI. Ornstein MC, et al. Among authors: allman kd. J Immunother Cancer. 2019 May 16;7(1):127. doi: 10.1186/s40425-019-0615-z. J Immunother Cancer. 2019. PMID: 31097024 Free PMC article. Clinical Trial.

10

Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study.

Ornstein MC, Pal SK, Wood LS, Tomer JM, Hobbs BP, Jia XS, Allman KD, Martin A, Olencki T, Davis NB, Gilligan TD, Mortazavi A, Rathmell WK, Garcia JA, Rini BI. Ornstein MC, et al. Among authors: allman kd. Lancet Oncol. 2019 Oct;20(10):1386-1394. doi: 10.1016/S1470-2045(19)30513-3. Epub 2019 Aug 16. Lancet Oncol. 2019. PMID: 31427205 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page